Clinical and laboratory profiles of Oropouche virus disease from the 2024 outbreak in Manaus, Brazilian Amazon.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gomes Mourão Maria Paula, de Melo Gisely Cardoso, Nascimento Joabi, Mwangi Victor Irungu, Sacchetto Livia, Gardinassi Luiz Gustavo, Linhares Abreu Netto Rebeca, Mota Jady, Pinto Sergio Damasceno, Tavares Mayara, Cordeiro Liz Moreira, de Castro Barbara Seffair, Brasil de Abreu, Porto Dyandra Dos Santos, Silva de Oliveira Bianca Daniele, Shuan Laco Ana Carolina, de Souza Lorenna Pereira, Bentes Karolaine Oliveira, Castilho Marcia, Morais Carlos Eduardo, Lira Heline Silva, Alho Luís Felipe, Martínez Espinosa Flor Ernestina, Sampaio Vanderson, Murta Felipe, Sartim Marco Aurélio, Nogueira Maurício Lacerda, Lacerda Marcus, Monteiro Wuelton
Аннотация
METHODS: This study analyzed 51 OROV and 78 of DENV cases consecutively enrolled in Manaus, Amazonas, Brazil, and monitored for 28 days. OROV diagnosis was performed by real-time PCR (RT-PCR) using serum and urine samples. OROV RT-PCR positive samples were genotyped. A paired Plaque Reduction Neutralization Test (PRNT) was conducted on samples collected at D1 and D28. Patients with a ≥ 4-fold increase in neutralizing antibody titer between D1 and D28 were considered OROV-positive. Clinical manifestations, hematology, biochemistry, and cytokine profiles were analyzed. Statistical analysis included comparison between OROV and DENV patients.
RESULTS: Genome sequencing of OROV isolates confirmed presence of a previously reported novel reassortment event, consistent with ongoing localized transmission. Urine RT-PCR demonstrated low positivity compared to serum samples. The paired PRNT increased sensitivity in 45%. Clinically, OROV infection was associated with significantly higher frequencies of severe headache, myalgia, arthralgia, and rash compared to DENV infection (p < 0.001). Elevated alanine aminotransferase (ALT) levels were also observed in OROV patients (p < 0.001). Immunologically, OROV infection induced significantly increased levels of acute-phase CCL11 (eotaxin), CXCL10, IFN-γ, IL-1RA, and IL-10, which declined by day 28, while IL-5 increased during recovery. In contrast, DENV patients exhibited elevated levels of CCL2, G-CSF, and CCL3 in recovery phase.
CONCLUSION: OROV symptoms overlap with DENV underscores the need for syndromic diagnostic approach in endemic regions. Continued genomic surveillance and expanded clinical studies are vital to assess long-term consequences. Given OROV's expanding geographic range, targeted public health measures are essential to mitigate future outbreaks and better understand its pathophysiology.